DOCSLIB.ORG

HOUSE BILL 674 E4, J1 0Lr0100

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HOUSE BILL 674 E4, J1 0Lr0100 HOUSE BILL 674 E4, J1 0lr0100 By: Chair, Judiciary Committee (By Request – Departmental – Health) Introduced and read first time: January 29, 2020 Assigned to: Judiciary A BILL ENTITLED 1 AN ACT concerning 2 Controlled Dangerous Substances – Schedules 3 FOR the purpose of altering the lists of substances designated as controlled dangerous 4 substances under certain schedules under the Maryland Controlled Dangerous 5 Substances Act; making stylistic changes; and generally relating to schedules for 6 controlled dangerous substances. 7 BY repealing and reenacting, with amendments, 8 Article – Criminal Law 9 Section 5–402 through 5–406 10 Annotated Code of Maryland 11 (2012 Replacement Volume and 2019 Supplement) 12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 13 That the Laws of Maryland read as follows: 14 Article – Criminal Law 15 5–402. 16 (a) Schedule I consists of each controlled dangerous substance: 17 (1) listed in this section; 18 (2) added to Schedule I by the Department under § 5–202(b) of this title; or 19 (3) designated as a Schedule I controlled dangerous substance by the 20 federal government unless the Department objects under § 5–202(f) of this title. 21 (b) Unless specifically excepted under this subtitle or listed in another schedule, 22 any of the following opiates, including their isomers, including optical and geometric EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW. [Brackets] indicate matter deleted from existing law. *hb0674* 2 HOUSE BILL 674 1 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the 2 existence of such isomers, esters, ethers, or salts is possible within the specific chemical 3 designation, are substances listed in Schedule I: 4 (1) [acetyl–alpha–methylfentanyl] ACETYL–ALPHA–METHYLFENTANYL 5 (N–[1–(1–METHYL–2–PHENETHYL)–4–PIPERIDINYL]–N–PHENYLACETAMIDE); 6 (2) acetylmethadol; 7 (3) [acetyl fentanyl 8 (n–(1–phenethylpiperidine–4–yl)–n–phenylacetamide)] ACETYL FENTANYL 9 (N–(1–PHENETHYLPIPERIDIN–4–YL)–N–PHENYLACETAMIDE); 10 (4) ACRYL FENTANYL 11 (N–(1–PHENETHYLPIPERIDIN–4–YL)–N–PHENYLACRYLAMIDE; 12 (5) [ah–7921 13 (3,4–dichloro–n–[(1–dimethylamino)cyclohexylmethyl])benzamide] AH–7921 14 (3,4–DICHLORO–N–[(1–DIMETHYLAMINO) CYCLOHEXYLMETHYL]) BENZAMIDE; 15 [(5)] (6) allylprodine; 16 [(6)] (7) alphacetylmethadol, except [levoalphacetylmethadol] 17 LEVO–ALPHACETYLMETHADOL; 18 [(7)] (8) alphameprodine; 19 [(8)] (9) alphamethadol; 20 [(9)] (10) [alpha–methylfentanyl] ALPHA–METHYLFENTANYL 21 (N–[1–(ALPHA–METHYL–BETA–PHENYL)ETHYL–4–PIPERIDYL] PROPIONANILIDE; 22 1–(1–METHYL–2–PHENYLETHYL)–4–(N–PROPANILIDO) PIPERIDINE); 23 [(10)] (11) [alpha–methylthiofentanyl] ALPHA–METHYLTHIOFENTANYL 24 (N–[1–METHYL–2–(2–THIENYL)ETHYL–4–PIPERIDINYL]–N– 25 PHENYLPROPANAMIDE); 26 [(11)] (12) benzethidine; 27 [(12)] (13) betacetylmethadol; 28 [(13)] (14) [beta–hydroxyfentanyl] BETA–HYDROXYFENTANYL 29 (N–[1–(2–HYDROXY–2–PHENETHYL)–4–PIPERIDINYL]–N–PHENYLPROPANAMIDE); 30 [(14)] (15) beta–hydroxy–3–methylfentanyl; HOUSE BILL 674 3 1 (16) N–[1–[2–HYDROXY–2–(THIOPHEN–2–YL)ETHYL]PIPERIDIN–4– 2 YL]–N–PHENYLPROPIONAMIDE; 3 [(15)] (17) betameprodine; 4 [(16)] (18) betamethadol; 5 [(17)] (19) betaprodine; 6 (20) BUTYRYL FENTANYL 7 (N–(1–PHENETHYLPIPERIDIN–4–YL)–N–PHENYLBUTYRAMIDE); 8 [(18)] (21) clonitazene; 9 [(19)] (22) dextromoramide; 10 [(20)] (23) diampromide; 11 [(21)] (24) diethylthiambutene; 12 [(22)] (25) difenoxin; 13 [(23)] (26) dimenoxadol; 14 [(24)] (27) dimepheptanol; 15 [(25)] (28) dimethylthiambutene; 16 [(26)] (29) dioxaphetyl butyrate; 17 [(27)] (30) dipipanone; 18 [(28)] (31) ethylmethylthiambutene; 19 [(29)] (32) etonitazene; 20 [(30)] (33) etoxeridine; 21 (34) 4–FLUOROISOBUTYRYL FENTANYL 22 (N–(4–FLUOROPHENYL)–N–(1–PHENETHYLPIPERIDIN–4–YL)ISOBUTYRAMIDE; 23 (35) FURANYL FENTANYL 24 (N–(1–PHENETHYLPIPERIDIN–4–YL)–N–PHENYLFURAN–2–CARBOXAMIDE); 4 HOUSE BILL 674 1 [(31)] (36) furethidine; 2 [(32)] (37) hydroxypethidine; 3 [(33)] (38) ketobemidone; 4 [(34)] (39) levomoramide; 5 [(35)] (40) levophenacylmorphan; 6 [(36)] (41) [3–methylfentanyl 7 (n–3–methyl–1–(2–phenylethyl)–4–piperidyl–1–n–phenylpropanamide)] 8 3–METHYLFENTANYL (N–[3–METHYL–1–(2–PHENYLETHYL)–4–PIPERIDYL]–N– 9 PHENYLPROPANAMIDE); 10 [(37)] (42) 3–methylthiofentanyl; 11 [(38)] (43) morpheridine; 12 [(39)] (44) MPPP (1–methyl–4–phenyl–4–propionoxypiperidine); 13 (45) MT–45 (1–CYCLOHEXYL–4–(1,2–DIPHENYLETHYL)PIPERAZINE); 14 [(40)] (46) noracymethadol; 15 [(41)] (47) norlevorphanol; 16 [(42)] (48) normethadone; 17 [(43)] (49) norpipanone; 18 (50) OCFENTANIL (N–(2–FLUOROPHENYL)–2–METHOXY–N–(1– 19 PHENETHYLPIPERIDIN–4–YL)ACETAMIDE); 20 [(44)] (51) para–fluorofentanyl (N–(4–FLUOROPHENYL)–N–[1–(2– 21 PHENETHYL)–4–PIPERIDINYL] PROPANAMIDE; 22 [(45)] (52) PEPAP [(1–(2–phenethyl)–4–phenyl–4–acetoxypiperidine)] 23 (1–(–2–PHENETHYL)–4–PHENYL–4–ACETOXYPIPERIDINE); 24 [(46)] (53) phenadoxone; 25 [(47)] (54) phenampromide; 26 [(48)] (55) phenomorphan; HOUSE BILL 674 5 1 [(49)] (56) phenoperidine; 2 [(50)] (57) piritramide; 3 [(51)] (58) proheptazine; 4 [(52)] (59) properidine; 5 [(53)] (60) propiram; 6 [(54)] (61) racemoramide; 7 (62) TETRAHYDROFURANYL FENTANYL 8 (N–(1–PHENETHYLPIPERIDIN–4–YL)–N–PHENYLTETRAHYDROFURAN–2– 9 CARBOXAMIDE); 10 [(55)] (63) thiofentanyl; 11 [(56)] (64) tilidine; [and] 12 [(57)] (65) [trimeperidin] TRIMEPERIDINE; AND 13 (66) U–47700 14 (3,4–DICHLORO–N–[2–(DIMETHYLAMINO)CYCLOHEXYL]–N–METHYLBENZAMIDE). 15 (c) Unless specifically excepted under this subtitle or listed in another schedule, 16 any of the following opium derivatives, including their salts, isomers, and salts of isomers, 17 whenever the existence of such salts, isomers, or salts of isomers is possible within the 18 specific chemical designation, are substances listed in Schedule I: 19 (1) acetorphine; 20 (2) acetyldihydrocodeine; 21 (3) benzylmorphine; 22 (4) codeine methylbromide; 23 (5) codeine–N–oxide; 24 (6) cyprenorphine; 25 (7) desomorphine; 26 (8) dihydromorphine; 6 HOUSE BILL 674 1 (9) drotebanol; 2 (10) etorphine (except hydrochloride salt); 3 (11) heroin; 4 (12) hydromorphinol; 5 (13) methyldesorphine; 6 (14) methyldihydromorphine; 7 (15) morphine methylbromide; 8 (16) morphine methylsulfonate; 9 (17) morphine–N–oxide; 10 (18) myrophine; 11 (19) nicocodeine; 12 (20) nicomorphine; 13 (21) normorphine; 14 (22) pholcodine; and 15 (23) thebacon. 16 (d) Unless specifically excepted under this subtitle or listed in another schedule, 17 any material, compound, mixture, or preparation that contains any quantity of the 18 following hallucinogenic substances, or that contains any of its salts, isomers, including 19 optical, position, and geometric isomers, or salts of isomers, whenever the existence of such 20 salts, isomers, or salts of isomers is possible within the specific chemical designation, is a 21 substance listed in Schedule I: 22 (1) alpha–ethyltryptamine; 23 (2) 4–bromo–2,5–dimethoxy–amphetamine; 24 (3) 4–bromo–2,5–dimethoxyphenethylamine; 25 (4) 2,5–dimethoxyamphetamine; 26 (5) 2,5–dimethoxy–4–ethylamphetamine (DOET); HOUSE BILL 674 7 1 (6) [2,5–dimethoxy–4–(n)–propylthiophenethylamine (2c–t–7)] 2 2,5–DIMETHOXY–4–(N)–PROPYLTHIOPHENETHYLAMINE (2C–T–7); 3 (7) 4–methoxyamphetamine (PMA); 4 (8) 5–methoxy–3,4–methylenedioxy–amphetamine; 5 (9) 4–methyl–2,5–dimethoxy–amphetamine; 6 (10) 3,4–methylenedioxy amphetamine; 7 (11) 3,4–methylenedioxymethamphetamine (MDMA); 8 (12) [3,4–methylenedioxy–n–ethylamphetamine] 9 3,4–METHYLENEDIOXY–N–ETHYLAMPHETAMINE (MDA); 10 (13) [n–hydroxy–3,4–methylenedioxyamphetamine] 11 N–HYDROXY–3,4–METHYLENEDIOXYAMPHETAMINE; 12 (14) 3,4,5–trimethoxyamphetamine; 13 (15) [5–methoxy–n, n–dimethyltryptamine] 14 5–METHOXY–N, N–DIMETHYLTRYPTAMINE; 15 (16) alpha–methyltryptamine (AMT); 16 (17) bufotenine; 17 (18) diethyltryptamine (DET); 18 (19) dimethyltryptamine (DMT); 19 (20) [5–methoxy–n, n–diisopropyltryptamine (5–MEO–DIPT)] 20 5–METHOXY–N, N–DIISOPROPYLTRYPTAMINE (5–MEO–DIPT); 21 (21) ibogaine; 22 (22) lysergic acid diethylamide; 23 (23) marijuana; 24 (24) mescaline; 25 (25) [parahexyl] PARAHEXYL–7374; 8 HOUSE BILL 674 1 (26) peyote (meaning all parts of the plant presently classified botanically 2 as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract 3 from any part of such plant, and every compound, manufacture, salt, derivative, mixture, 4 or preparation of such plant, its seeds, or extracts); 5 (27) [n–ethyl–3–piperidyl benzilate] N–ETHYL–3–PIPERIDYL 6 BENZILATE; 7 (28) [n–methyl–3–piperidyl benzilate] N–METHYL–3–PIPERIDYL 8 BENZILATE; 9 (29) psilocybin; 10 (30) psilocyn; 11 (31) tetrahydrocannabinols; 12 (32) ethylamine analog of phencyclidine 13 (N–ethyl–1–phenylcyclohexylamine); 14 (33) pyrrolidine analog of phencyclidine 15 (1–(1–phenylcyclohexyl)–pyrrolidine); 16 (34) [thiophene analog of phencyclidine 17 (1–(1–(2–thienyl)–cyclohexyl)–piperidine)] THIOPHENE ANALOG OF PHENCYCLIDINE 18 (1–[1–(2–THIENYL)–CYCLOHEXYL]–PIPERIDINE); 19 (35) 1–[1–(2–thienyl)cyclohexyl]pyrrolidine; 20 (36) 4–METHYLMETHCATHINONE (MEPHEDRONE); 21 (37) 3, 4–methylenedioxypyrovalerone (MDPV); 22 [(37) 4–methylmethcathinone (mephedrone); 23 (38) 4–methoxymethcathinone (methedrone);] 24 [(39)] (38) [2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2c–e)] 25 2–(2,5–DIMETHOXY–4–ETHYLPHENYL) ETHANAMINE (2C–E); 26 [(40)] (39) [2–(2,5–dimethoxy–4–methylphenyl) ethanamine (2c–d)] 27 2–(2,5–DIMETHOXY–4–METHYLPHENYL) ETHANAMINE (2C–D); 28 [(41)] (40) [2–(4–chloro–2,5–dimethoxyphenyl) ethanamine (2c–c)] 29 2–(4–CHLORO–2,5–DIMETHOXYPHENYL) ETHANAMINE (2C–C); HOUSE BILL 674 9 1 [(42)]
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • CRITERIA for DRUG COVERAGE Solriamfetol (Sunosi)
    Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE Solriamfetol (Sunosi) Notes: * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation Initiation (new start) criteria: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 12 months when the following criteria are met: • Prescribed by a Sleep Specialist • Prescribed for the treatment of excessive daytime sleepiness due to narcolepsy OR excessive daytime sleepiness due to obstructive sleep apnea (OSA) • Patient is 18 years of age or older • Patient has failed a trial of, or patient has an allergy or intolerance* to: o Modafinil or armodafinil AND o A stimulant medication (ie methylphenidate, dextroamphetamine, amphetamine salt combination, etc.) • OSA only: patient is currently treated for OSA [i.e. use of CPAP, or use of oral appliances (eg mandibular advancement device, tongue retaining devices), or had past OSA surgery] Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 24 months when the following criteria are met: • See above New Start criteria Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 12 months when the
    [Show full text]
  • BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18
    Oregon Board of Pharmacy BOARD MEETING AGENDA Meeting Location: Portland State Office Building 800 NE Oregon Street, Portland, OR 97232 June 6-7, 2018 Updated 6.4.18 The mission of the Oregon State Board of Pharmacy is to promote, preserve and protect the public health, safety and welfare by ensuring high standards in the practice of pharmacy and by regulating the quality, manufacture, sale and distribution of drugs. Wednesday, June 6, 2018 @ 8:30AM – Conference Rm A Thursday, June 7, 2018 @ 8:30AM – Conference Room A ≈ If special accommodations are needed for you to attend or participate in this Board Meeting, please contact Loretta Glenn at: (971) 673-0001. ≈ WEDNESDAY, JUNE 6, 2018 I. 8:30AM OPEN SESSION, Penny Reher, R.Ph, Presiding A. Roll Call B. Agenda Review and Approval Action Necessary II. Contested Case Deliberation pursuant to ORS 192.690(1) - Not Open to the Public III. EXECUTIVE SESSION – NOT OPEN TO THE PUBLIC, pursuant to ORS 676.175, ORS 192.660 (1) (2) (f) (k). A. Items for Consideration and Discussion: 1. Deliberation on Disciplinary Cases and Investigations 2. Personal Appearances 3. Deficiency Notifications 4. Case Review B. Employee Performance Review pursuant to ORS 192.660(2)(i). IV. OPEN SESSION - PUBLIC MAY ATTEND - At the conclusion of Executive Session, the Board may convene Open Session to begin some of the following scheduled agenda items - time permitting at approximately 3:30PM. V. Approve Consent Agenda* Action Necessary *Items listed under the consent agenda are considered to be routine agency matters and will be approved by a single motion of the Board without separate discussion.
    [Show full text]
  • Prezentace Aplikace Powerpoint
    P.719 NAPHYRONE – PHARMACOKINETICS AND BEHAVIOURAL PROFILE IN WISTAR RAT Olejíková Lucie, Štefková Kristýa, Šíchová Klára, Dada Hyek, Lhotková Eva, Piterová Nikola, Páleíček Toáš National Institute of Mental Health, Klecany, Czech Republic NAPHYRONE METHODS Naphyrone (naphthylpyrovalerone, O-2482, Energy 1), from the Naphyrone was administered subcutaneously to Wistar rats in a single dose of 5 cathinones group, is a drug derived from pyrovalerone that acts as a triple mg/kg, 10 mg/kg and 20 mg/kg. Open field test was performed in an empty black reuptake inhibitor, producing stimulant effects similar to cocaine, MDMA square arena (68 c × 68 c × 30 c). Rats were placed individually into the center of or amphetamines and has been reported as a novel psychoactive the arena 5 or 40 i after the drug administration (testing-onset) and their behavior was recorded for 30 i. Examined parameters were trajectory length, its spatial substance (NPS). characteristic (thigmotaxis and time spent in the center of the arena). Further the prepulse inhibition (PPI) of acoustic startle reaction (ASR) were determined in this study. Pharmacokinetic profile was analyzed using gas chromatography-mass spectrometry (GCMS). To simulate effects of crowded conditions, body temperature was monitored in animals housed in groups versus individually. Data were analyzed using factorial Analysis of Variance and independent t-tests. RESULTS LOCOMOTION PREPULSE INHIBITION OF ACOUSTIC STARTLE REACTION lenght (m) Trajectory Fig. 1: The effect of naphyrone on total locomotion 15 and 60 min after administration. Data are Fig. 3: The effect of naphyrone on prepulse inhibition (PPI) of acoustic startle reaction (ASR). PPI presented as mean±SEM.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Author(s): Peter Stout, Katherine Moore, Megan Grabenauer, Jeri Ropero-Miller Document No.: 241444 Date Received: March 2013 Award Number: 2010-DN-BX-K177 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Award Number: 2010-DN-BX-K177 July 16, 2012 Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Final Report Authors: Peter Stout Katherine Moore Megan Grabenauer Jeri Ropero-Miller This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Table of Contents Abstract ........................................................................................................................................... 1 Executive Summary .......................................................................................................................
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • 2020 Regular Session
    HOUSE BILL 674 E4, J1 0lr0100 By: Chair, Judiciary Committee (By Request – Departmental – Health) Introduced and read first time: January 29, 2020 Assigned to: Judiciary Committee Report: Favorable House action: Adopted Read second time: March 8, 2020 CHAPTER ______ 1 AN ACT concerning 2 Controlled Dangerous Substances – Schedules 3 FOR the purpose of altering the lists of substances designated as controlled dangerous 4 substances under certain schedules under the Maryland Controlled Dangerous 5 Substances Act; making stylistic changes; and generally relating to schedules for 6 controlled dangerous substances. 7 BY repealing and reenacting, with amendments, 8 Article – Criminal Law 9 Section 5–402 through 5–406 10 Annotated Code of Maryland 11 (2012 Replacement Volume and 2019 Supplement) 12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 13 That the Laws of Maryland read as follows: 14 Article – Criminal Law 15 5–402. 16 (a) Schedule I consists of each controlled dangerous substance: 17 (1) listed in this section; 18 (2) added to Schedule I by the Department under § 5–202(b) of this title; or EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW. [Brackets] indicate matter deleted from existing law. Underlining indicates amendments to bill. Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment. *hb0674* 2 HOUSE BILL 674 1 (3) designated as a Schedule I controlled dangerous substance by the 2 federal government unless the Department objects under § 5–202(f) of this title.
    [Show full text]
  • O~~~4 a Bill for an Act
    J~.B. NO. (O~~~4 A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: 1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is 2 amended by amending subsection (b) to read as follows: 3 “(b) Any of the following opiates, including their 4 isomers, esters, ethers, salts, and salts of isomers, esters, 5 and ethers, unless specifically excepted, whenever the existence 6 of these isomers, esters, ethers, and salts is possible within 7 the specific chemical designation: 8 (1) Acetyl—aipha—methylfentanyl (N—[1—(1—methyl—2— 9 phenethyl)—4-piperidinyl]—N—phenylacetamide) 10 (2) Acetylmethadol; 11 (3) Allylprodine; 12 (4) Alphacetylmethadol (except levo-alphacetylmethadol, 13 levomethadyl acetate, or LAAM) ; 14 ~(5) Aiphameprodine; 15 (6) Alphamethadoi; 16 (7) Alpha—methylfentanyl (N—[l—(alpha—methyl—beta— 17 phenyl)ethyl-4-piperidyl] propionanilide; 1-Cl-methyl- 18 2-phenylethyl)-4-(N-propanilido) piperidine); PSD—O1 (21) Page 2 Pi .B. NO. (O~ 1 (8) Aipha—methyithiofentanyl (N—[1—methyl—2—(2— 2 thienyl) ethyl-4-piperidinyl] -N-phenylpropanamide); 3 (9) Benzethidine; 4 (10) Betacetylmethadol; 5 (11) Beta—hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- 6 piperidinyl] -N-phenylpropanamide); 7 (12) Beta—hydroxy-3—methylfentanyl (N—[1—(2—hydroxy—2— 8 phenethyl) -3-methyl-4-piperidinyl] -N- 9 phenyipropanamide); 10 (13) Betameprodine; 11 (14) Betamethadol; 12 (15) Betaprodine; 13 (16) Clonitazene; 14 (17) Dextromoramide; 15 (18) Diampromide; 16 (19) Diethyithiambutene; 17 (20) Difenoxin; 18 (21) Dimenoxadol; 19 (22) Dimepheptanol; 20 (23) Dimethyithiambutene; 21 (24) Dioxaphetyl butyrate; 22 (25) Dipipanone; PSD—01 (21) Page 3 j~B.NO.
    [Show full text]
  • This List Was Originally Published in Virginia Register Volume 8, Issue 18
    In accordance with 6 VAC 40-30, the Regulations for the Approval of Field Tests for Detection of Drugs, and under the authority of the Code of Virginia, the following field tests for detection of drugs are approved field tests: O D V INCORPORATED 13386 INTERNATIONAL PARKWAY JACKSONVILLE, FLORIDA 32218-2383 ODV NarcoPouch Drug or Drug Type: Manufacturer’s Field Test: Heroin 902 – Marquis Reagent Amphetamine 902 – Marquis Reagent Methamphetamine 902 – Marquis Reagent 3,4–Methylenedioxymethamphetamine (MDMA) 902 – Marquis Reagent Cocaine Hydrochloride 904 or 904B – Cocaine HCl and Base Reagent Cocaine Base 904 or 904B – Cocaine HCl and Base Reagent Barbiturates 905 – Dille-Koppanyi Reagent Lysergic Acid Diethylamide (LSD) 907 – Ehrlich’s (Modified) Reagent Marijuana 908 – Duquenois – Levine Reagent Hashish Oil 908 – Duquenois – Levine Reagent Marijuana 909 – K N Reagent Hashish Oil 909 – K N Reagent Phencyclidine (PCP) 914 – PCP Methaqualone Reagent Heroin 922 – Opiates Reagent Methamphetamine 923 – Methamphetamine/Ecstasy Reagent 3,4–Methylenedioxymethamphetamine (MDMA) 923 – Methamphetamine/Ecstasy Reagent Heroin 924 – Mecke’s (Modified) Reagent Diazepam 925 – Valium/Ketamine Reagent Ketamine 925 – Valium/Ketamine Reagent Ephedrine 927 – Ephedrine Reagent gamma – Hydroxybutyrate (GHB) 928 – GHB Reagent ODV NarcoTest Drug or Drug Type: Manufacturer’s Field Test: Heroin 7602 – Marquis Reagent Amphetamine 7602 – Marquis Reagent Methamphetamine 7602 – Marquis Reagent 3,4–Methylenedioxymethamphetamine (MDMA) 7602 – Marquis Reagent Barbiturates
    [Show full text]